Novartis Ophthalmology announced they have entered into an agreement to acquire a topical treatment for presbyopia from Encore Vision Inc., a privately-held Texas based company. The announcement calls the new investigational product EV06 a “potentially disruptive innovation” and the first-in-class topical treatment for presbyopia.
EV06 has completed a phase I/II proof of concept study. The pro-drug restores the bilateral micro-fluidics of the crystalline lens through a biochemical mechanism of action.
In 2016, Novartis combined its retina medicines business with the Alcon pharmaceuticals business, now operating as one Ophthalmology franchise under Novartis Pharmaceuticals.
View the Novartis Press release here.
View Encore Vision’s discussion of the drug and clinical trials HERE.